Effects of Arabinoxylan-Oligosaccharides Compared to Other Prebiotics in Healthy Subjects

This study has been completed.
Sponsor:
Information provided by:
Katholieke Universiteit Leuven
ClinicalTrials.gov Identifier:
NCT00853034
First received: February 25, 2009
Last updated: February 26, 2009
Last verified: February 2009

February 25, 2009
February 26, 2009
October 2006
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00853034 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Effects of Arabinoxylan-Oligosaccharides Compared to Other Prebiotics in Healthy Subjects
Effects of Arabinoxylan-Oligosaccharides on Colonic Metabolism and Microbial Composition Compared to Other Prebiotics in Healthy Subjects

The purpose of the study is to evaluate the effects of arabinoxylan-oligosaccharides (AXOS) on the colonic metabolism and microbial composition, and to compare these effects with the reference prebiotic fructo-oligosaccharide enriched inulin.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Healthy
  • Dietary Supplement: FOS-IN

    prebiotic fructo-oligosaccharide enriched inulin

    intake period: 2 weeks, 1.25 or 2.50g every morning and evening

    Other Name: Synergy1, Orafti, Tienen
  • Dietary Supplement: AXOS

    arabinoxylan-oligosaccharides (AXOS)

    intake period: 2 weeks, 1.25 or 2.50g every morning and evening

  • Active Comparator: FOS-IN
    prebiotic fructo-oligosaccharide enriched inulin
    Intervention: Dietary Supplement: FOS-IN
  • Experimental: AXOS
    arabinoxylan-oligosaccharides (AXOS)
    Intervention: Dietary Supplement: AXOS
Cloetens L, De Preter V, Swennen K, Broekaert WF, Courtin CM, Delcour JA, Rutgeerts P, Verbeke K. Dose-response effect of arabinoxylooligosaccharides on gastrointestinal motility and on colonic bacterial metabolism in healthy volunteers. J Am Coll Nutr. 2008 Aug;27(4):512-8.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
September 2007
Not Provided

Inclusion Criteria:

  • healthy
  • 18-45 years
  • regular eating pattern

Exclusion Criteria:

  • gastrointestinal complaints
  • antibiotic intake
  • medication influencing gut transit or microbiota
  • abdominal surgery
  • pregnancy
Both
18 Years to 45 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Belgium
 
NCT00853034
AXOS 001
Yes
Not Provided
Katholieke Universiteit Leuven
Not Provided
Study Director: Kristin Verbeke, PhD Katholieke Universiteit Leuven
Katholieke Universiteit Leuven
February 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP